Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Early breast cancer, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ?20%,for the adjuvant treatment of adult patients (in combination with endocrine therapy)
Last updated:
July 18, 2023
Status:
Concluded with an LOI
Manufacturer:
Mitsubishi Tanabe Pharma Canada, Inc.
Indication:
Amyotrophic Lateral Sclerosis (ALS)
Last updated:
July 10, 2023
Status:
Concluded with an LOI
Manufacturer:
Teva Canada Ltd.
Indication:
Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy
Last updated:
July 7, 2023
Rylaze (crisantaspase recombinant)
Status:
Concluded with an LOI
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Indication:
Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase.
Last updated:
July 4, 2023
Status:
Negotiations were not pursued
Manufacturer:
Celgene Inc.
Indication:
Acute Myeloid Leukemia (AML)
Last updated:
June 29, 2023
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Osteoporosis
Last updated:
June 28, 2023
Status:
Concluded with an LOI
Manufacturer:
EMD Serono Canada, a division of EMD Inc.
Indication:
Non-small cell lung cancer (NSCLC), locally advanced unresectable metastatic, harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations, in adult patients
Last updated:
June 22, 2023
Status:
Concluded with an LOI
Manufacturer:
Lundbeck Canada Inc.
Indication:
Migraine, prevention
Last updated:
June 16, 2023
Albrioza (sodium phenylbutyrate and ursodoxicoltaurine)
Status:
Concluded with an LOI
Manufacturer:
Amylyx Canada
Indication:
Amyotrophic Lateral Sclerosis (ALS)
Last updated:
June 12, 2023
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer, for adjuvant treatment of adult patients who have been treated with neoadjuvant or adjuvant chemotherapy
Last updated:
June 6, 2023